Sorafenib in combination with capecitabine: An oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 13, 2012, Pages 1484-1491

  Baselga, José ^a   Segalla, José Getúlio Martins ^b   Roché, Henri ^l   Del Giglio, Auro ^c   Pinczowski, Hélio ^c   Ciruelos, Eva M ⁿ   Cabral Filho, Sebastião ^d   Gómez, Patricia ^o   Van Eyll, Brigitte ^e   Bermejo, Begoña ^s   Llombart, Antonio ^u   Garicochea, Bernardo ⁱ   Durán, Miguel Ángel Climent ^t   Hoff, Paulo Marcelo Gehm ^f   Espié, Marc ^m   Gemeinder De Moraes, Andre Augusto ^g   Ribeiro, Ronaldo Albuquerque ^j   Mathias, Clarissa ^k   Gil, Miguel Gil ^p   Ojeda, Belén ^q   Morales, Josefa ^r   Ro, Sunhee Kwon ^v   Li, Shell ^v   Costa, Frederico ^h   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b Fundação Doutor Amaral Carvalho   (Brazil)

^c FACULDADE DE MEDICINA DO ABC   (Brazil)

^d Clinica de Olhos da Santa Casa de Belo Horizonte   (Brazil)

^e Instituto do Cancer Dr Arnaldo   (Brazil)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g Centro do Cancer da Santa Casa de Piracicaba São Paulo   (Brazil)

^h Instituto Brasileiro de Controle do Cancer   (Brazil)

ⁱ PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^j Cancer Hospital of Ceará   (Brazil)

^k Hospital Português da Bahia   (Brazil)

^l INSTITUT CLAUDIUS REGAUD   (France)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^o VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^p CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^q HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^r Tratamiento Y Otras Estrategias Experimentales en Tumores Solidos   (Spain)

^s HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^t INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^u HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^v ONYX PHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLACEBO; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; HER2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HAZARD RATIO; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; AGED; BRAZIL; BREAST TUMOR; CANCER INVASION; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; ENZYMOLOGY; EUROPE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BRAZIL; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTOR, ERBB-2; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84862988257     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.7771     Document Type: Article

References (42)

1. Bernard-Marty C, Cardoso F, Piccart MJ: Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9:617-632, 2004 (Pubitemid 39546403)
2. Carrick S, Parker S, Thornton CE, et al: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2:CD003372, 2009
3. Olin JJ, Muss HB: New strategies for managing metastatic breast cancer. Oncology (Williston Park) 14:629-641, 2000
4. Banerjee S, Dowsett M, Ashworth A, et al: Mechanisms of disease: Angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4:536-550, 2007 (Pubitemid 47351464)
5. Fox SB, Generali DG, Harris AL: Breast tumour angiogenesis. Breast Cancer Res 9:216-226, 2007
6. Schneider BP, Miller KD: Angiogenesis of breast cancer. J Clin Oncol 23:1782-1790, 2005 (Pubitemid 46211430)
7. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
8. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992 (Pubitemid 23004615)
9. Hansen S, Grabau DA, Sørensen FB, et al: The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 6:139-146, 2000 (Pubitemid 30064986)
10. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
11. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
12. Brufsky AM, Hurvitz S, Perez E, et al: RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for secondline treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286-4293, 2011
13. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247, 2010
14. Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011
15. Barrios CH, Liu MC, Lee SC, et al: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121-131, 2010
16. Crown J, Dieras V, Staroslawska E, et al: Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 28:18s, 2010 (suppl; abstr LBA1011)
17. Bergh J, Greil R, Voytko N, et al: Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 28:18s, 2010 (suppl; abstr LBA1010)
18. Bianchi G, Loibl S, Zamagni C, et al: Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 20:616-624, 2009
19. Moreno-Aspitia A, Morton RF, Hillman DW, et al: Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 27:11-15, 2009
20. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997 (Pubitemid 27441066)
21. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004 (Pubitemid 38524883)
22. Borgström P, Hillan KJ, Sriramarao P, et al: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56:4032-4039, 1996 (Pubitemid 26284756)
23. Roy V, Perez EA: Biologic therapy of breast cancer: Focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Res Treat 116:31-38, 2009
24. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004 (Pubitemid 39331023)
25. Wilhelm S, Carter C, Lynch M, et al: Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835-844, 2006 (Pubitemid 44480537)
26. Wilhelm SM, Adnane L, Newell P, et al: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140, 2008
27. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
28. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
29. Dal Lago L, D'Hondt V, Awada A: Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors. Oncologist 13:845-858, 2008
30. Awada A, Gil T, Whenham N, et al: Phase I dose-escalation trial evaluating the safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors. Ann Oncol 18:iv39, 2007 (suppl; abstr 402)
31. Fleming TR, Richardson BA: Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis 190:666-674, 2004 (Pubitemid 39049994)
32. Ershler WB: Capecitabine monotherapy: Safe and effective treatment for metastatic breast cancer. Oncologist 11:325-335, 2006
33. Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
34. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999 (Pubitemid 29075232)
35. Robert NJ, Dieras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27:18s, 2009 (suppl; abst 1005)
36. Yuan F, Chen Y, Dellian M, et al: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93:14765-14770, 1996 (Pubitemid 26419043)
37. Oshaughnessy JA, Blum J, Moiseyenko V, et al: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as firstline therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247-1254, 2001 (Pubitemid 32994752)
38. Pàez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
39. Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239, 2009
40. Miles D, Harbeck N, Escudier B, et al: Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials. J Clin Oncol 29:83-88, 2011
41. Findlay M, von Minckwitz G, Wardley A: Effective oral chemotherapy for breast cancer: Pillars of strength. Ann Oncol 19:212-222, 2008 (Pubitemid 351201700)
42. Dodd LE, Korn EL, Freidlin B, et al: Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? J Clin Oncol 26:3791-3796, 2008